Ultragenyx Pharmaceutical Inc. Stock price
Equities
RARE
US90400D1081
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.69 USD | -0.28% | +0.09% | -2.36% |
Financials (USD)
Sales 2024 * | 515M | Sales 2025 * | 633M | Capitalization | 3.84B |
---|---|---|---|---|---|
Net income 2024 * | -532M | Net income 2025 * | -453M | EV / Sales 2024 * | 6.82 x |
Net cash position 2024 * | 334M | Net cash position 2025 * | 298M | EV / Sales 2025 * | 5.6 x |
P/E ratio 2024 * |
-7.24
x | P/E ratio 2025 * |
-9.06
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.88% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | -0.28% | ||
1 week | +0.09% | ||
Current month | -9.73% | ||
1 month | -11.49% | ||
3 months | -3.27% | ||
6 months | +32.76% | ||
Current year | -2.36% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | -.--% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 46.69 | -0.28% | 543,698 |
24-03-27 | 46.82 | +2.99% | 551,352 |
24-03-26 | 45.46 | +0.09% | 362,335 |
24-03-25 | 45.42 | -0.94% | 442,715 |
24-03-22 | 45.85 | -1.71% | 403,665 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.36% | 3.84B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |